AYER, Mass.--(BUSINESS WIRE)--Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the introduction of two new low protein foods: Pea-Not Butter and Tortilla Chips in both Sea Salt and Sweet Chili flavors.
Available in 8 oz jars, Cambrooke’s low protein Pea-Not Butter, is a creamy rich peanut butter flavored spread for sandwiches or as a great addition to low protein recipes. Unlike regular peanut butter, Pea-Not Butter has only 0.65g protein and 31 mg of phe per 1 T/28 grams and should be stored in the refrigerator.
Cambrooke’s low protein Tortilla Chips come in two delicious flavors. Both Sea Salt and Sweet Chili flavors are tasty snacks that can be enjoyed on their own or with favorite dips or salsa. Sold in a box of 25 single serve bags, each bag contains 0.2 grams of protein and 3 mg of phe per 28 grams/1 bag (sea salt) and 0.2 grams of protein and 3 mg of phe per 28 grams/1 bag (sweet chili).
Lynn Paolella, Cambrooke founder and vice president of food innovation said, “I continue to work hard in developing new foods that are both great for my two children with PKU, but also tasty for people without PKU who would not even know they are modified to be low in protein.”
“As a mother of a teenager with PKU, I am always looking to find something new for my daughter to try. Seeing Cambrooke Foods' new Pea-Not Butter was just what I was looking for and with the recipes that Cambrooke has to offer there are multiple ways to use it. I also saw the new Tortilla Chips that Cambrooke came out with and can’t wait to order those and other low protein food items that will be coming out soon,” said Doris Nagel, Flemington, NJ.
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.